drugset
Drugs / BOLD-100
last change Sep 2026 re-read 9 days ago

BOLD-100

Small molecule

Developed for
cholangiocarcinoma · colorectal cancer · gastric cancer · malignant pancreatic neoplasm · soft tissue sarcoma
Investigated by
Bold Therapeutics, Inc. · University Health Network, Toronto

Trials 2

today NCT07027423 · Ph 1 NCT04421820 · Ph 1/2
2021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT07027423 Mar 2026 → Jan 2027 expected soft tissue sarcoma University Health Network, Toronto Not yet recruiting No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT04421820 Aug 2020 → Jun 2026 overdue cholangiocarcinoma, colorectal cancer, gastric cancer, malignant pancreatic neoplasm Bold Therapeutics, Inc. Recruiting No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2020-05-28 Hana Pharm Co., Ltd. 하나제약, “캐나다 Bold Therapeutics의 표적항암제 BOLD-100 옵션 계약 체결” hanaph.co.kr ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as BOLD-100 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04421820 ↗
1

NCT07027423 ↗
Action Inhibit “BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when compared to normal cells.” NCT04421820 ↗
Modality Small molecule “BOLD-100 is a novel, targeted anti-cancer therapy which is an intravenously administered small molecule drug.” NCT04421820 ↗
Route Intravenous “BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule.” NCT04421820 ↗